Clicky

Bristol-Myers Squibb Company(BRM) News

Date Title
Jul 1 Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Jul 1 Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
Jun 30 Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?
Jun 30 BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
Jun 30 Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
Jun 30 AbbVie to buy Capstan for up to $2.1 billion in immunology push
Jun 27 FDA approves label updates for BMS’ CAR T cell therapies
Jun 27 Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies
Jun 27 U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Jun 26 Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
Jun 26 Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Jun 26 Incyte replaces CEO Hoppenot with dealmaker Meury
Jun 25 Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst
Jun 25 Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Jun 25 3 Top Dividend Stocks to Maximize Your Retirement Income
Jun 20 Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Jun 19 Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Jun 19 How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Jun 19 Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Jun 18 Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends